Page contentsKey factsDecisionRelated contentKey facts Invented name Forxiga Active Substance dapagliflozin Therapeutic area Infectious diseases Decision number P/0444/2020 PIP number EMEA-000694-PIP05-20 Pharmaceutical form(s) Film-coated tablet Condition(s) / indication(s) Treatment of Coronavirus disease 2019 (COVID-19) Route(s) of administration Oral use Contact for public enquiries AstraZeneca ABTel. +46 8553 27591E-mail: paediatrics@astrazeneca.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 01/12/2020DecisionP/0444/2020: EMA decision of 1 December 2020 on the granting of a product specific waiver for dapagliflozin (Forxiga), (EMEA-000694-PIP05-20)AdoptedReference Number: EMA/599228/2020 Corr English (EN) (221.03 KB - PDF)First published: 19/08/2021ViewRelated contentForxigaShare this page